XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation	Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, cancer, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, intestinal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, rectal disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, thyroid gland disorder, thyroid tumor	Not yet recruiting	Phase 1 / Phase 2	2025-04-10		NCT05275374

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Xynomic Pharmaceuticals, Inc.	7

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.